Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects

Journal of Allergy and Clinical Immunology

Volumn 102, Issue 2, 1998, Pages 177-183

  Hamilton, Allan ^a   Faiferman, Isidore ^b   Stober, Paul ^b   Watson, Richard M ^a   O'Byrne, Paul M ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b SmithKline Beecham Pharma   (Canada)

Author keywords

Allergens; Asthma; Cysteinyl leukotriene receptor antagonist; Pranlukast

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPYLSULFONYL] 3 OXO 4 PHENYLBUTYRIC ACID; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPYLTHIO]PHENYL] 4 HYDROXY 3 METHYLBUTYRIC ACID; ALLERGEN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHACHOLINE; PEPTIDOLEUKOTRIENE; PRANLUKAST; TOMELUKAST; VERLUKAST; ZAFIRLUKAST;

ADULT; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR BLOCKING; TREATMENT OUTCOME;

EID: 0031754251     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(98)70083-1     Document Type: Article

References (53)

1. O'Byrne PM, Dolovich J, Hargreave FE. State of the art: late asthmatic responses. Am Rev Respir Dis 1987;136:740-51.
2. Cockcroft DW, Ruffin RE, Dolovich J, Hargreave FE. Allergen-induced increase in non-allergic bronchial reactivity. Clin Allergy 1977;7:503-13.
3. Cartier A, Thomson NC, Frith PA, Roberts R, Hargreave FE. Allergen-induced increase in bronchial responsiveness to histamine: relationship to the late asthmatic response and change in airway caliber. J Allergy Clin Immunol 1982;70:170-7.
4. De Monchy JGR, Kauffman HF, Venge P, Koeter GH, Jansen HM, Sluiter HJ, et al. Bronchoalveolar eosinophilia during allergen-induced late asthmatic reaction. Am Rev Respir Dis 1985;131:373-6.
5. Dahlen S-E, Hedqvist P, Hammarstrom S, Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature 1980;288:484-6.
6. Hanna CJ, Bach MK, Pare PD, Schellenberg RR. Slow-reacting substances (leukotrienes) contract human airway and pulmonary vascular smooth muscle in vitro. Nature 1981;290:343-4.
7. 4, and histamine in normal human subjects. Thorax 1984;39:500-4.
8. 4 and to methacholine in patients with asthma and normal controls. N Engl J Med 1986;315:480-4.
9. Davidson AB, Lee TH, Scanlon PD, Solway J, McFadden ER, Ingram RH, et al. Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjects. Am Rev Respir Dis 1987;135:333-7.
10. Drazen JM, Austen KF. State of the art: leukotrienes and airway responses. Am Rev Respir Dis 1987;136:985-98.
11. Wenzel SE, Larsen GL, Johnston K, Voelkel NF, Westcott JY. Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 1990;142:112-9.
12. 4 levels during early and late asthmatic response4. J Allergy Clin Immunol 1990;86:211-20.
13. 4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989;1:584-7.
14. Woodward DF, Wasserman MA, Weichmann BM. Investigation of leukotriene involvement in the vasopermeability response associated with guinea-pig tracheal anaphylaxis: comparison with cutaneous anaphylaxis. Eur J Pharmacol 1983;93:9-19.
15. 4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982;126:449-51.
16. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991;337:690-4.
17. 4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol 1992;90:193-201.
18. Friedman BS, Bel EH, Buntinx A, Tanaka W, Han Y-HR, Shingo S, et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis 1993;147:839-44.
19. Diamant Z, Timmers MC, van der Veen H, Friedman BS, de Smet M, Depre M, et al. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol 1995;95:42-51.
20. Hamilton AL, Watson RM, Wyile G, O'Byrne PM. Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005. Thorax 1997;52:348-54.
21. Obata T, Katsube N, Miyamoto T, Toda M, Okegawa T, Nakai H, et al. New antagonists of leukotrienes: ONO-RS-411 and ONO-RS-347. Adv Prostaglandin Thromboxane Leukot Res 1985;15:229-31.
22. 4 and antigen in vitro. Am Rev Respir Dis 1992;146:923-9.
23. 4) challenge in normal volunteers. Thorax 1997;52:519-22.
24. Taniguchi Y, Tamura G, Honma M, Aizawa T, Maruyama N, Shirato K, et al. The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J Allergy Clin Immunol 1993;92:507-12.
25. 4. Eur Respir J 1995;8(suppl 19):P1447.
26. Grossman J, Faiferman I, Dubb JW, Tompson DJ, Busse W, Bronsky E, et al. Results of the first U.S. Double-blind, placebo-controlled, multi-center clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist. J Asthma 1997;34:321-8.
27. Barnes NC, Pujet J-C. Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax 1997;52:523-7.
28. Fujimura M, Sakamoto S, Kamio Y, Matsuda T. Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma. Resp Med 1993;87:133-8.
29. Taki F, Suzuki R, Torii K, Matsumoto S, Taniguchi H, Takagi K. Reduction of the severity of bronchial hyperresponsiveness by the novel leukotriene antagonist 4-Oxo-8- (4- (4-phenyl-butoxy) benzoylamino)-2-(tetrazol-5-yl)-4H-1-benzopyran Hemihydrate. Drug Res 1994;44:330-3.
30. Crapo RO, Morris AH, Gardiner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981;123:659-64.
31. Cockcroft DW, Murdock KY, Kirby J, Hargreave FE. Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine. Am Rev Respir Dis 1987;135:264-7.
32. Cockcroft DW, Killian DN, Mellon JJA, Hargreave FE. Bronchial reactivity of inhaled histamine: a method and clinical survey. Clin Allergy 1977;7:235-43.
33. Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmac 1979;8:7-20.
34. 4-induced bronchoconstriction in normal man. J Allergy Clin Immunol 1987;79:816-21.
35. 4 in atopic subjects. J Allergy Clin Immunol 1989;83:439-44.
36. Adaikan PG, Lau LC, Kottegoda SR, Ratnam SS. Effects of two new leukotriene antagonists ONO-RS-347 and ONO-RS-411 (ONO-1078) on the guinea pig and human respiratory and other systems. Adv Prostaglandin Thromboxane Leukot Res 1987;17:549-53.
37. Diamant Z, Timmers MC, van der Veen H, De Smet M, Leff JA, Friedman BS, et al. Effect of oral montelukast (MK-0476), a potent leukotriene receptor antagonist, on allergen-induced airway responses in asthmatic subjects [abstract]. Am J Respir Crit Care Med 1996;153:346.
38. Adams GK, Lichtenstein L. In vitro studies of antigen-induced bron-chospasm: effect of antihistamine and SRS-A antagonist on response of sensitized guinea pig and human airways to antigen. J Immunol 1979;122:555-62.
39. Roquet A, Dahlen B, Ihre E, Zetterstrom O, Lundgren G, Karlsson O, et al. Cysteinyl-leukotrienes and histamine account for the predominant components of early and late phase airway obstruction evoked by allergen-challenge of asthmatics [abstract]. Am J Respir Crit Care Med 1996;153:214.
40. 4 in allergic sheep. Prostaglandins 1985;29:715-26.
41. 4 does not cause a late asthmatic response in atopic subjects [abstract], J Allergy Clin Immunol 1987;79:141.
42. 4 and granulocytic infiltration into asthmatic airways. Lancet 1993;341:989-90.
43. 4 in subjects with mild asthma [abstract]. Am J Respir Crit Care Med 1997;155:1247-53.
44. Calhoun WJ, Havins BJ, Minkwitz MC, Evans R, Gleich GJ, Cohn J. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage findings after segmented allergen challenge. Am J Respir Crit Care Med 1998;157:1381-9.
45. Inman MD, Hamilton AL, Kerstjens HAM, Watson RW, O'Byrne PM. The utility of methacholine airway responsiveness measurements in evaluating anti-asthma drugs. J Allergy Clin Immunol 1998;101:342-8.
46. 4 and platelet-activating factor on airway reactivity in normal subjects. Am Rev Respir Dis 1990;141:993-7.
47. 4 in normal subjects. Am Rev Respir Dis 1986;133:1127-32.
48. Barnes NC, Watson A, Piper PJ, Costello JF. Action of inhaled leukotriene C and D on large and small airways: effect of preinhalation of leukotriene D on histamine dose-response curve [abstract]. Am Rev Respir Dis 1984;129:1.
49. 4 and methacholine in normal subjects in vivo. Am Rev Respir Dis 1989;139:427-31.
50. 4 on the airway responsiveness to histamine in subjects with asthma and normal subjects. J Allergy Clin Immunol 1988;82:654-60.
51. O'Byrne PM, Hargreaves FE, Kirby JG. Airway inflammation and hyperresponsiveness. Am Rev Respir Dis 1987;136:S35-7.
52. 4-induced airway hyperresponsiveness of guinea pig tracheal smooth muscle to histamine and evidence for three separate sulfidopeptide leukotriene receptors. Proc Natl Acad Sci 1984;81:4922-5.
53. Kirby JG, Hargreave FE, Cockcroft DW, O'Byrne PM. Effect of indomethacin on allergen-induced asthmatic responses. J Appl Physiol 1989;66:578-83.